Advertisement

Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Document › Details

Pierre Fabre S.A.. (10/7/21). "Press Release: Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration with Pierre Fabre". Victoria, BC & Castres.

Organisations Organisation Pierre Fabre S.A.
  Group Pierre Fabre (Group)
  Organisation 2 ImmunoPrecise Antibodies Ltd. (TSX.V : IPA OTCQB:IPATF)
  Group ImmunoPrecise (Group)
Products Product drug discovery
  Product 2 therapeutic antibody
Person Person Lang, Stefan (ImmunoPrecise 202110 CBO formerly Aldevron 201112 Aldevron Freiburg GmbH)
     


Multi-target research collaboration leverages ImmunoPrecise’s powerful antibody discovery technologies with the long-standing expertise of Pierre Fabre in immuno-oncology


IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) and the Pierre Fabre pharmaceutical group announced today that IPA’s subsidiary, Talem Therapeutics LLC (“Talem”), and Pierre Fabre have entered a multi-year, multi-target research collaboration with the goal to discover and develop therapeutics antibodies for up to nine targets. This strategic collaboration is expected to help expand Talem’s portfolio of novel antibodies across oncology. It adds to the variety of diverse relationships that the IPA group of companies holds across the pharmaceutical and biotechnology sector.

Under the research collaboration, scientists from both companies will work together and contribute their respective resources to discover and develop novel antibodies leveraging the IPA group’s antibody discovery technologies, such as B cell Select™ or Deep Display™ using wild-type and/or transgenic animals, available human libraries, as well as their signature “end-to-end" services. The antibodies developed in the research collaboration against the selected targets will be jointly owned by Talem and Pierre Fabre and, following the completion of each target specific research program, Pierre Fabre will have an option to obtain an exclusive worldwide license to Talem’s interest in those jointly discovered antibodies against that particular target, and Talem would be eligible to receive certain up-front and contingent downstream payments. In addition, if licensed, Pierre Fabre will be responsible for the preclinical and clinical development, as well as the commercialization of the jointly discovered antibodies.


“Less than two years ago we started Talem Therapeutics to provide a unique partnering opportunity for companies to jointly seek the development of promising novel candidate. We are very excited to join forces with Pierre Fabre, combining our advanced antibody technologies with their world-class expertise in immuno-oncology is a powerful strategic combination enabling the teams to jointly address life threatening human diseases.”

Dr. Stefan Lang
Chief Business Officer of ImmunoPrecise


“Drug discovery in immuno-oncology is a priority for Pierre Fabre. We are therefore very pleased to enter this multi-target research collaboration. Talem will provide us with its expertise and a variety of technology platforms to enable the discovery of therapeutic antibodies, towards a set of structurally diverse targets.”

Francesco Hofmann
Head of R&D at Pierre Fabre Medical Care


About Pierre Fabre

Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world, the 2nd largest private French pharmaceutical group and the market leader in France for products sold over the counter in pharmacies. Its portfolio ranges across several medical franchises and international brands, including Pierre Fabre Oncology, Pierre Fabre Dermatology, Eau Thermale Avène, Klorane, Ducray, René Furterer, A-Derma, Naturactive and Pierre Fabre Oral Care. In 2020, Pierre Fabre generated €2.3 billion in revenues, 65% of which came from international sales. The Group employs some 10,000 people worldwide.

Pierre Fabre enjoys a 35-year long experience in oncology covering innovation, development, manufacturing and commercialization. Its Medical Care division has declared oncology as its main R&D and commercial priority, focusing on targeted therapies, biotherapies and immuno-oncology. Its therapeutic areas include high unmet medical needs, and cover colorectal, breast, lung cancers, melanoma, and pre-cancerous conditions like actinic keratosis.

Pierre Fabre is 86%-owned by the Pierre Fabre Foundation, a government-recognized public-interest foundation, and secondarily by its own employees through an international employee stock ownership plan. In 2020, Ecocert Environment assessed the Group’s corporate social & environmental responsibility approach in accordance with the ISO 26000 sustainable development standard for the 2nd consecutive year and confirmed its “Excellence” level.

For further information, visit www.pierre-fabre.com


About ImmunoPrecise Antibodies Ltd

ImmunoPrecise is an innovation-driven technology platform company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. The Company endeavors to transform the conventional multi-vendor antibody discovery model by providing a comprehensive suite of services tailored to optimize antibody genetic diversity and epitope coverage, to discover antibodies against rare and/or challenging epitopes.

For further information, visit www.immunoprecise.com


About Talem Therapeutics LLC

Talem Therapeutics is a subsidiary of ImmunoPrecise Antibodies Ltd. and is focused on the discovery and development of next-generation, human, monoclonal, therapeutic antibodies. Using the proprietary antibody discovery platforms and innovative technologies housed at IPA, Talem aims to accelerate novel, therapeutic antibody treatments to the clinic through strategic alliances and partners.


IPA investor contact:

LifeSci Advisors
John Mullaly
E-mail : jmullaly@lifesciadvisors.com

Media Relations Pierre Fabre:
Anne Kerveillant, Communication Manager
Phone : +33 1 49 10 81 60 / +33 (0)6 20 88 54 57
E-mail : anne.kerveillant@pierre-fabre.com

   
Record changed: 2021-10-10

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Pierre Fabre (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture [iito] Plain Stupid Simple 650x80px




» top